Makary says FDA will remove pharma representatives from advisory panels

FDA Removing Pharmaceutical Representatives From Advisory Panels

The Food and Drug Administration (FDA) is removing pharmaceutical company representatives from advisory committees in a bid to limit industry influence. Dr. Marty Makary, the FDA’s new commissioner, issued a directive that eliminates the role of pharmaceutical representative. “Industry employees are welcome to attend FDA advisory committee meetings, along with the rest of the American public, but having industry employees serve as official membe…

FDA Announces New Policy on Advisory Committee Members

The policy announced by Commissioner Martin A. Makary, MD, will not preclude employees of regulated companies from presenting their views to committees, and rare exceptions will be allowed.

New FDA head says no more pharma on advisory committees

New FDA head says no more pharma on advisory committees Jonah.Comstock Fri, 18/04/2025 - 17:43 Bookmark this

Makary seeks to limit industry’s role in FDA advisory panels

Commissioner Martin Makary said the agency would, whenever possible, restrict drug company employees from participating as industry representatives on advisory committees.

Dr. Marty Makary Responds to Critiques From Former Top FDA Vaccine Official Over Direction of Agency * WorldNetDaily * by Megyn Kelly

President Trump’s FDA Chief Boots Big Pharma from Advisory Panels

FDA Commissioner Dr. Marty Makary just dropped the hammer. He’s saying no more pharma insiders on FDA advisory panels. Well, it’s about time. He says the agency needs independent scientific reviews, not industry influence. On Megyn Kelly’s podcast, Makary agreed it’s time to cut ties that blur trust and transparency. The phrase that comes to mind is “conflict of interest”. RedState reports: President Donald Trump’s head of the Food and Drug Admi…